METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors


Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).

Aim(s): To evaluate the efficacy and safety of metformin monotherapy in non-diabetic NET pts.

Materials and methods: Single-arm phase II trial of metformin 850mg PO twice daily until progression or intolerance for non-diabetic pts with progressive metastatic G1 or G2 gastroenteropancreatic NET (NCT02279758). The primary endpoint was disease control rate (DCR) by RECIST 1.1 at 6 months. Secondary endpoints were: clinical and radiological response rate, PFS, toxicity and variations in glycemia, glycated hemoglobin and peptide C kinetics at baseline and at every 90 days.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Glasberg J

Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,

Keywords: neuroendocrine tumors, metformin, clinical trial,

To read the full abstract, please log into your ENETS Member account.